Lukang Pharmaceutical Q3 profit plunges 27% as prior year asset sales boost fades

Shandong Lukang Pharmaceutical reported a net profit attributable to shareholders of 34,361,228.02 yuan for the third quarter of 2025, a 27.04% decrease compared to the same period last year. Total operating revenue for the quarter reached 1,470,356,873.74 yuan, an increase of 5.97%, however, total profit declined by 15.58% to 43,403,798.27 yuan.

For the first nine months of 2025, net profit attributable to shareholders plummeted by 59.32% to 141,196,204.70 yuan. The profit decline is largely attributed to significant asset disposal income from land acquisition and storage in the prior year, which had boosted profits in 2024. Basic and diluted earnings per share also fell by 58.97% to 0.16 yuan for the nine-month period.

As of September 30, 2025, the company's total assets were 8,816,367,162.43 yuan, a 3.10% decrease from the end of the previous year. Net cash flow from operating activities for the first nine months was 305,942,559.58 yuan, down 24.41% year-over-year.